

NICE TA 266 – Mannitol dry powder for inhalation for treating cystic fibrosis

1	<p>Summary of NICE TA 266</p> <p>Mannitol dry powder for inhalation is recommended as an option for treating cystic fibrosis in adults:</p> <ul style="list-style-type: none">• who cannot use rhDNase because of ineligibility, intolerance or inadequate response to rhDNase <p>and</p> <ul style="list-style-type: none">• whose lung function is rapidly declining (forced expiratory volume in 1 second [FEV₁] decline greater than 2% annually) <p>and</p> <ul style="list-style-type: none">• for whom other osmotic agents are not considered appropriate. <p>People currently receiving mannitol whose cystic fibrosis does not meet the criteria above should be able to continue treatment until they and their clinician consider it appropriate to stop.</p>
2	<p>Number of people in Northern Ireland expected to take up service/therapy (new cases per year)</p> <p>The NICE costing template accompanying TA 268 indicates that 5-6 patients per year would be expected to take up treatment with mannitol for cystic fibrosis.</p> <p>However, an estimate of the existing patient profile of cases of cystic fibrosis based on local clinical data indicates that there are likely to be up to 30 – 35 cases in 2013/14 based on cumulative unmet need with 2-5 new cases per year thereafter.</p> <p>The treatment pool is likely to remain at this level as there will be natural attrition from the eligible group.</p> <p>The HSCB will support the introduction of TA 266 using the local clinical data on the basis that local clinicians are best placed to take account of local variations which contribute to this higher uptake in Northern Ireland. It is acknowledged that there is a relatively high incidence of this disease and excellent treatment which improves patient survival.</p> <p>This position will be closely monitored and may be subject to review over the next 18-24 months.</p>

3	Costs
3.1	Cost per patient per annum The guidance states that the list price for a 14-day pack of 280 capsules and 2 inhalers is £231.66. This equates to £0.83 per 40 mg capsule or an average cost of £16.55 per day, including the cost of the inhaler (£16.55 x 365 = £6401 per annum).
3.2	In year cost per patient per annum (for new and prevalent cases) Not applicable
3.3	Cost savings and how these will be secured It is anticipated that there will be cost savings associated with a reduction in hospital admissions, demand for physiotherapy and use of antibiotics.
3.4	Recurrent overall cost Year 1 (2013/14) – 30 cases on a phased basis as per unmet need = 30 x £6401 = £192,030 Year 2 (2014/15) – up to 30 cases as per the existing patient group + up to 5 cases = (30x £6401) + (5 x 6401) = £192,030 + £32,005 = £224,035 recurrently The NICE costing statement assumes that no administration costs apply.
4	Expected implementation period There is no impediment to immediate implementation for new patients. Treatment for the backlog of patients due to unmet need can also be commenced immediately.
5	Commissioning arrangements This regime will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team.
6	Monitoring arrangements Belfast Trust will be required to provide Specialist Services Commissioning Team on a quarterly basis commencing 2013/14 with details of patients commencing treatment to include the number of patients that have been given the drug and the cost of the drug per patient and confirmation that each patient complies with the NICE requirements for this treatment. It will also be included in their Annual Report for Cystic Fibrosis.

7

Legislative / policy caveats

This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.